iver protective drug action of homoeopathic preparation of Myrica cerifera 3C on Non alcoholic fatty liver disease

Not Applicable

• Conditions: Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified

• Registration Number: CTRI/2022/02/040009
• Lead Sponsor: Dr Raja Manoharan

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 17 October 2022

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

Conformed Diagnosis of NAFLD established by ultrasound.

There is no significant alcohol consumption

There are no competing aetiologies for hepatic steatosis

There are no co existing causes for chronic liver disease

Alanine transaminase (ALT) more than 40 UL as considered elevated.

Providing written informed consent to participate.

Exclusion Criteria

Absence of regular or excessive use of alcohol (more than 20 gram per day in men and 10 gram in female).

History of bowel surgery, Bariatric surgery or undergoing evaluation for bariatric surgery

for obesity, extensive small bowel resection or orthotopic liver transplants.

History of other chronic liver disease (Viral hepatitis B or C, autoimmune hepatitis, Cholestatic and metabolic liver diseases) and hemochromatosis.

Known case of cirrhosis

Patients with Hypothyroidism

History of myopathies or evidence of active muscle disease.

History of bladder disease and /or haematuria or has haematuria except due to UTI.

Pregnant women, Lactating women & paediatric age group ( < 18yrs)

Uncontrolled Diabetes, Hypertension, Mental illness or depression, kidney or heart disease, Malignant conditions as well as with history of stroke.

Person under corticosteroid therapy.

Patients who are too sick for consultation and not willing to cooperate

Unwilling to take part and not giving consent to join the study

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<br/ ><br>Total bilirubin ALT AST Prothrombin time Albumin Globulin ratioTimepoint: All the parameters will be assessed at baseline after 2 months and after 4 months

Secondary Outcome Measures

Name	Time	Method
SG (Whole abdomen) alkaline phosphatase.Timepoint: alkaline phosphatase will be assessed baseline after 2 months and after 4 months and USG (Whole abdomen) will be assessed baseline and after 4 months